Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

描述（由申请人提供）：本申请申请要求资金，以帮助获得治疗多发性骨髓瘤的有前途的新型候选药物商业化所需的必要额外临床前数据。一家名为调制治疗公司的小企业已经从莫菲特癌症中心及其员工Priyesh Jain博士那里获得了这项技术的许可，该公司与莫菲特癌症中心的Mark McLaughlin博士和洛里Hazlehurst博士合作，并得到了共同研究者Richard Lush，PharmD的帮助，提出合成预期具有更好的生物利用度并改善或维持对CD44的直接结合亲和力的类似物，IC50活性。我们将在资助的第1阶段中测量初步PK研究以及体外和体内5TGM1 MM肿瘤生长抑制的确证性研究。 公共卫生相关性：该申请要求提供资金，以帮助一家新的小型企业Modulation Therapeutics Incorporated获得必要的额外临床前数据，这些数据是治疗多发性骨髓瘤的有前途的新型候选药物商业化所需的。这种新的候选药物可以杀死人类多发性骨髓瘤，这是人类第二常见的血液恶性肿瘤，在免疫受损的小鼠中植入人类肿瘤，对小鼠没有明显的毒性。

DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. A small business, Modulation Therapeutics Incorporated, has licensed this technology from the Moffitt Cancer Center and its employee, Dr. Priyesh Jain, in collaboration with Dr. Mark McLaughlin and Dr. Lori Hazlehurst at Moffitt Cancer Center and aided by co-investigator Richard Lush, PharmD, are proposing to synthesize analogs expected to have better bioavailability and that improve or maintain direct binding affinities for CD44 and in vitro IC50 activity. We will measure preliminary PK studies, and confirmatory in vitro and in vivo 5TGM1 MM tumor growth inhibition studies in Phase 1 of the grant. PUBLIC HEALTH RELEVANCE: This application requests funds to aid a new small business, Modulation Therapeutics Incorporated, in obtaining the necessary additional pre-clinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. The new drug candidate kills human multiple myeloma tumors, the second most common hematological malignancy in humans, in immune-compromised mice implanted with the human tumor at does that show no obvious toxicity to the mice.